Notice - Prescription Drug List (PDL): Levonorgestrel

May 29, 2015
Our file number: 15-106112-465

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for levonorgestrel on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged. Health Canada has conducted a scientific review of levonorgestrel against a set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The wording, which remains unchanged from what was proposed in the November 28, 2014 Notice of Intent to amend, is:

Drugs containing any of the following: Sex Hormones

Qualifier: except Levonorgestrel when sold as a single ingredient in an oral dosage form containing no more than 1.5 milligrams (mg)

Effective Date: date of this Notice

Should you have any questions on this update to the Prescription Drug List, please contact:

Prescription Drug Status Committee
Health Canada
Holland Cross, Tower B, 2nd Floor
1600 Scott Street
Address Locator 3102C3
Ottawa, Ontario
K1A 0K9

Email: drug_prescription_status-statut_d'
Phone: 613-957-1058
Fax: 613-941-5035

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: